Japan Tissue Engineering Co., Ltd. (7774.T)
JPY 460.0
(-2.54%)
JPY 460.0
(-2.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.51 Billion JPY | 23.7% |
| 2022 | 2.03 Billion JPY | -3.38% |
| 2021 | 2.1 Billion JPY | -6.83% |
| 2020 | 2.25 Billion JPY | -2.26% |
| 2019 | 2.3 Billion JPY | -2.04% |
| 2018 | 2.35 Billion JPY | 3.8% |
| 2017 | 2.27 Billion JPY | 6.39% |
| 2016 | 2.13 Billion JPY | 49.22% |
| 2015 | 1.43 Billion JPY | 8.27% |
| 2014 | 1.32 Billion JPY | 31.09% |
| 2013 | 1 Billion JPY | 78.83% |
| 2012 | 563.7 Million JPY | 19.02% |
| 2011 | 473.6 Million JPY | 34.71% |
| 2010 | 351.57 Million JPY | 66.1% |
| 2009 | 211.65 Million JPY | 84.49% |
| 2008 | 114.72 Million JPY | 2.66% |
| 2007 | 111.75 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 442.31 Million JPY | -39.29% |
| 2024 Q2 | 719.54 Million JPY | 62.68% |
| 2023 Q1 | 662.13 Million JPY | 12.45% |
| 2023 Q2 | 584.46 Million JPY | -11.73% |
| 2023 FY | 2.51 Billion JPY | 23.7% |
| 2023 Q3 | 539.03 Million JPY | -7.77% |
| 2023 Q4 | 728.55 Million JPY | 35.16% |
| 2022 FY | 2.03 Billion JPY | -3.38% |
| 2022 Q1 | 422.72 Million JPY | -16.78% |
| 2022 Q2 | 549.46 Million JPY | 29.98% |
| 2022 Q3 | 471.42 Million JPY | -14.2% |
| 2022 Q4 | 588.83 Million JPY | 24.9% |
| 2021 Q2 | 502.38 Million JPY | 5.03% |
| 2021 FY | 2.1 Billion JPY | -6.83% |
| 2021 Q1 | 478.34 Million JPY | -45.29% |
| 2021 Q3 | 614.77 Million JPY | 22.37% |
| 2021 Q4 | 507.94 Million JPY | -17.38% |
| 2020 Q3 | 466.39 Million JPY | -13.48% |
| 2020 Q2 | 539.06 Million JPY | 42.67% |
| 2020 Q1 | 377.84 Million JPY | -53.05% |
| 2020 FY | 2.25 Billion JPY | -2.26% |
| 2020 Q4 | 874.3 Million JPY | 87.46% |
| 2019 FY | 2.3 Billion JPY | -2.04% |
| 2019 Q3 | 521.57 Million JPY | -5.24% |
| 2019 Q2 | 550.42 Million JPY | 27.11% |
| 2019 Q1 | 433.01 Million JPY | -47.22% |
| 2019 Q4 | 804.84 Million JPY | 54.31% |
| 2018 Q3 | 514.31 Million JPY | -14.15% |
| 2018 FY | 2.35 Billion JPY | 3.8% |
| 2018 Q1 | 424.15 Million JPY | -35.98% |
| 2018 Q2 | 599.07 Million JPY | 41.24% |
| 2018 Q4 | 820.37 Million JPY | 59.51% |
| 2017 Q3 | 518.93 Million JPY | -10.89% |
| 2017 Q2 | 582.35 Million JPY | 14.7% |
| 2017 FY | 2.27 Billion JPY | 6.39% |
| 2017 Q1 | 507.72 Million JPY | -48.24% |
| 2017 Q4 | 662.49 Million JPY | 27.67% |
| 2016 FY | 2.13 Billion JPY | 49.22% |
| 2016 Q4 | 980.83 Million JPY | 153.15% |
| 2016 Q3 | 387.44 Million JPY | -4.62% |
| 2016 Q2 | 406.2 Million JPY | 12.63% |
| 2016 Q1 | 360.65 Million JPY | -23.96% |
| 2015 Q2 | 375.59 Million JPY | 17.13% |
| 2015 Q3 | 260.26 Million JPY | -30.71% |
| 2015 Q4 | 474.29 Million JPY | 82.23% |
| 2015 FY | 1.43 Billion JPY | 8.27% |
| 2015 Q1 | 320.67 Million JPY | -32.56% |
| 2014 Q2 | 215.93 Million JPY | -27.72% |
| 2014 Q4 | 475.48 Million JPY | 43.51% |
| 2014 FY | 1.32 Billion JPY | 31.09% |
| 2014 Q1 | 298.76 Million JPY | -9.72% |
| 2014 Q3 | 331.31 Million JPY | 53.43% |
| 2013 Q3 | 257.31 Million JPY | 30.82% |
| 2013 Q1 | 223.12 Million JPY | 31.45% |
| 2013 FY | 1 Billion JPY | 78.83% |
| 2013 Q4 | 330.92 Million JPY | 28.61% |
| 2013 Q2 | 196.69 Million JPY | -11.85% |
| 2012 Q1 | 94.78 Million JPY | -32.84% |
| 2012 FY | 563.7 Million JPY | 19.02% |
| 2012 Q4 | 169.74 Million JPY | 12.15% |
| 2012 Q3 | 151.35 Million JPY | 2.39% |
| 2012 Q2 | 147.82 Million JPY | 55.95% |
| 2011 FY | 473.6 Million JPY | 34.71% |
| 2011 Q1 | 129.62 Million JPY | 15.45% |
| 2011 Q4 | 141.13 Million JPY | 36.91% |
| 2011 Q3 | 103.08 Million JPY | 3.33% |
| 2011 Q2 | 99.76 Million JPY | -23.03% |
| 2010 Q1 | 73.07 Million JPY | 8.74% |
| 2010 Q3 | 92.66 Million JPY | 25.97% |
| 2010 Q4 | 112.27 Million JPY | 21.16% |
| 2010 Q2 | 73.56 Million JPY | 0.67% |
| 2010 FY | 351.57 Million JPY | 66.1% |
| 2009 FY | 211.65 Million JPY | 84.49% |
| 2009 Q3 | 47.86 Million JPY | -33.98% |
| 2009 Q2 | 72.5 Million JPY | 201.05% |
| 2009 Q1 | 24.08 Million JPY | -27.81% |
| 2009 Q4 | 67.19 Million JPY | 40.38% |
| 2008 FY | 114.72 Million JPY | 2.66% |
| 2008 Q3 | 21.19 Million JPY | -43.29% |
| 2008 Q2 | 37.37 Million JPY | 64.02% |
| 2008 Q1 | 22.78 Million JPY | 0.0% |
| 2008 Q4 | 33.36 Million JPY | 57.41% |
| 2007 FY | 111.75 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 47.293% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -2126.405% |
| GNI Group Ltd. | 26.01 Billion JPY | 90.334% |
| Linical Co., Ltd. | 12.3 Billion JPY | 79.573% |
| Trans Genic Inc. | 13.08 Billion JPY | 80.783% |
| MEDINET Co., Ltd. | 661.54 Million JPY | -280.049% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 51.261% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | -61.126% |
| AnGes, Inc. | 152.98 Million JPY | -1543.423% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | -312.083% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 80.306% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | -207.847% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -1755.381% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | -54.635% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -486.928% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | -32.242% |
| Chiome Bioscience Inc. | 682.46 Million JPY | -268.399% |
| Kidswell Bio Corporation | 2.43 Billion JPY | -3.412% |
| PeptiDream Inc. | 28.71 Billion JPY | 91.243% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -3888.372% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -1977.843% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -3491830.556% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -6203.282% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 44.26% |
| FunPep Company Limited | 530 Thousand JPY | -474275.472% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -3530.599% |
| Stella Pharma Corporation | 269.49 Million JPY | -832.94% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -693.575% |
| Cuorips Inc. | 23.1 Million JPY | -10782.997% |
| K Pharma,Inc. | 1 Billion JPY | -151.419% |
| Takara Bio Inc. | 43.5 Billion JPY | 94.221% |
| ReproCELL Incorporated | 2.42 Billion JPY | -3.6% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | -46.573% |
| StemCell Institute Inc. | 2.48 Billion JPY | -1.33% |
| CellSeed Inc. | 190.13 Million JPY | -1222.325% |